NCT04128085View on ClinicalTrials.gov

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2021

Conditions
Advanced Malignant Tumors
Interventions
DRUG

TQB3804

A kind of tyrosine kinase inhibitor.

Trial Locations (1)

510050

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY